Impact of Esmya on Fertility to Infertile Women With Fibroids Managed With Assisted Reproduction Techniques

CompletedOBSERVATIONAL
Enrollment

127

Participants

Timeline

Start Date

December 29, 2017

Primary Completion Date

June 30, 2018

Study Completion Date

January 8, 2019

Conditions
Infertility, FemaleFibroid Uterus
Interventions
DRUG

ULIPRISTAL ACETATE

Ulipristal Acetate (Esmya) administrated for fibroids indication before surgery and IVF/ICSI procedure(retrospective study)

Trial Locations (23)

Unknown

Chu Angers, Angers

Chu Besancon, Besançon

Chu Pellegrin, Bordeaux

Polyclinique Jean Villar, Bruges

Centre Hospitalier Intercommunal Creteil, Créteil

Chu Dijon, Dijon

Clinique Val D'Ouest, Écully

Chru Lille, Lille

Cpma Marseille, Marseille

Imr Rocca, Marseille

Chevalier, Montpellier

POUGET, Montpellier

CHU NICE, Nice

Chu Nimes, Nîmes

Ch Antoine Beclere, Paris

CH TENON, Paris

Maternite Bichat, Paris

MENARD, Paris

Port Royal - Chirurgie, Paris

Chu Rennes, Rennes

Cmco - University Hospitals of Strasbourg, Schiltigheim

Chu Toulouse, Toulouse

Centre Hospitalier Territorial Gaston Bourret, Noumea

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gedeon Richter Plc.

INDUSTRY

lead

ASSOCIATION POUR LE DEVELOPPEMENT EN FECONDATION IN VITRO

OTHER

NCT03349190 - Impact of Esmya on Fertility to Infertile Women With Fibroids Managed With Assisted Reproduction Techniques | Biotech Hunter | Biotech Hunter